Daiichi Sankyo Company Analysis
Daiichi Sankyo Company Analysis
$3,000.00
PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Updated analysis and forecasts based on Q1 2017 company-reported sales.
PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Snapshot
- 2021 outlook – Top line will fall by $600m as generics erode olmesartan franchise.
- 2026 outlook – Growth in the CNS, hematology, and oncology portfolios will fail to offset losses in cardiovascular diseases, and revenue will fall by over $600m.
- Events – Injectafer and Savaysa will continue to gain uptake, but clinical setbacks will hinder CNS and oncology products.
Highlights
- Daiichi Sankyo’s prescription pharmaceutical sales will decrease over the forecast period.
- The company’s cardiovascular portfolio will be its largest growth resistor.
- Analgesics will drive growth in the CNS portfolio.
- The value of Daiichi Sankyo’s hematology portfolio will build on the early success of Injectafer and increase over the forecast period.
- The establishment of Daiichi Sankyo’s oncology portfolio has been weakened by late-stage pipeline failures.
Model updates
- Tivantinib removed.
- Patritumab removed.
- Fibromyalgia approval for Mirogabalin removed.
- Delayed CL-108 launch.
- Added abuse-deterrent labeled products MorphaBond ER and RoxyBond XR.
Analysis structure
Company context
- How is Daiichi Sankyo strategically poised out to 2026?
- What are Daiichi Sankyo’s key strengths, weaknesses, opportunities, and threats?
- What are Daiichi Sankyo’s key catalysts over the next four quarters?
Facts and figures
- What is Daiichi Sankyo’s forecasted sales performance out to 2026?
- What is the revenue trajectory of Daiichi Sankyo’s current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Daiichi Sankyo based on the lifecycle of its products?
Key therapy areas
- Why will specific therapy areas will experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Daiichi Sankyo’s important therapeutic markets?
- How is Daiichi Sankyo adapting strategically to internal and external headwinds?
TABLE OF CONTENTS
5 EXECUTIVE SUMMARY
6 COMPANY CONTEXT
6 2025 Vision
6 Oncology refocus
6 Expanding US and Japan business
7 Outlook
7 Daiichi Sankyo’s SWOT analysis
8 Daiichi Sankyo’s key events and catalysts
10 FACTS AND FIGURES
10 Daiichi Sankyo’s prescription pharma sales outlook
14 Daiichi Sankyo’s top 10 products over 2016–26
14 Daiichi Sankyo’s growth drivers and resistors
20 Daiichi Sankyo’s launch/core/expiry analysis
22 Daiichi Sankyo’s financial outlook
23 Daiichi Sankyo’s M&A history
25 KEY THERAPY AREAS
28 Benicar will cease to be Daiichi Sankyo’s biggest selling drug due to patent expiry
28 Savaysa/Lixiana’s limited uptake will not be enough to counter declining sales from Benicar
28 Black box warning hinders Savaysa’s US uptake
29 Real-world evidence key to maximizing Savaysa/Lixiana value
29 Approval of AndexXa as an antidote will take market share from rival Pradaxa
29 Central nervous system
34 Hematology
36 Oncology
41 BIBLIOGRAPHY
LIST OF FIGURES
10 Figure 1: Daiichi Sankyo’s prescription pharmaceutical sales ($m) and growth rate (%), 2013–26
11 Figure 2: Daiichi Sankyo’s therapy area dynamics, 2016–26
14 Figure 3: Daiichi Sankyo’s current top 10 product sales ($m), 2016–26
20 Figure 4: Daiichi Sankyo’s launch/core/expiry analysis, 2016–26
22 Figure 5: Daiichi Sankyo’s operating revenue/cost analysis ($m), 2009–20
LIST OF TABLES
12 Table 1: Daiichi Sankyo’s sales by therapy area ($m), 2016–26
15 Table 2: Daiichi Sankyo’s key products, 2016–26
21 Table 3: Daiichi Sankyo’s sales by launch, core, and expiry portfolio ($m), 2016–26
23 Table 4: Daiichi Sankyo’s financial performance ($m), 2015–21
24 Table 5: Daiichi Sankyo’s key merger and acquisition deals, 2003–17
26 Table 6: Daiichi Sankyo’s cardiovascular portfolio sales, by product ($m), 2016–26
31 Table 7: Daiichi Sankyo’s central nervous system portfolio sales, by product ($m), 2016–26
35 Table 8: Daiichi Sankyo’s hematology portfolio sales, by product ($m), 2016–26
38 Table 9: Daiichi Sankyo’s oncology portfolio sales, by product ($m), 2016–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Specialty Endoscopic Surgery Devices Market 
Sign up to the